372 related articles for article (PubMed ID: 36817420)
21. Sjögren's syndrome in dermatology.
Fox RI; Liu AY
Clin Dermatol; 2006; 24(5):393-413. PubMed ID: 16966020
[TBL] [Abstract][Full Text] [Related]
22. Disturbance of cytokine networks in Sjögren's syndrome.
Youinou P; Pers JO
Arthritis Res Ther; 2011 Jul; 13(4):227. PubMed ID: 21745420
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunological parameters of Sjögren's syndrome.
Psianou K; Panagoulias I; Papanastasiou AD; de Lastic AL; Rodi M; Spantidea PI; Degn SE; Georgiou P; Mouzaki A
Autoimmun Rev; 2018 Oct; 17(10):1053-1064. PubMed ID: 30103041
[TBL] [Abstract][Full Text] [Related]
24. Thrombospondin-derived peptide attenuates Sjögren's syndrome-associated ocular surface inflammation in mice.
Contreras Ruiz L; Mir FA; Turpie B; Masli S
Clin Exp Immunol; 2017 Apr; 188(1):86-95. PubMed ID: 28033649
[TBL] [Abstract][Full Text] [Related]
25. Human umbilical cord mesenchymal stem cells confer potent immunosuppressive effects in Sjögren's syndrome by inducing regulatory T cells.
Liu Y; Li C; Wang S; Guo J; Guo J; Fu J; Ren L; An Y; He J; Li Z
Mod Rheumatol; 2021 Jan; 31(1):186-196. PubMed ID: 31859545
[TBL] [Abstract][Full Text] [Related]
26. Sjögren's syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving TACE/NF-κB.
Lisi S; Sisto M; Lofrumento DD; D'Amore M
Lab Invest; 2012 Apr; 92(4):615-24. PubMed ID: 22157716
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation.
Bikker A; van Woerkom JM; Kruize AA; Wenting-van Wijk M; de Jager W; Bijlsma JW; Lafeber FP; van Roon JA
Arthritis Rheum; 2010 Apr; 62(4):969-77. PubMed ID: 20131250
[TBL] [Abstract][Full Text] [Related]
28. Secreted factors from dental pulp stem cells improve Sjögren's syndrome via regulatory T cell-mediated immunosuppression.
Matsumura-Kawashima M; Ogata K; Moriyama M; Murakami Y; Kawado T; Nakamura S
Stem Cell Res Ther; 2021 Mar; 12(1):182. PubMed ID: 33726818
[TBL] [Abstract][Full Text] [Related]
29. Advances in Mast Cell Activation by IL-1 and IL-33 in Sjögren's Syndrome: Promising Inhibitory Effect of IL-37.
Conti P; Stellin L; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560266
[TBL] [Abstract][Full Text] [Related]
30. Advances in the diagnosis and treatment of Sjogren's syndrome.
Chen X; Wu H; Wei W
Clin Rheumatol; 2018 Jul; 37(7):1743-1749. PubMed ID: 29804149
[TBL] [Abstract][Full Text] [Related]
31. B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.
Varin MM; Le Pottier L; Youinou P; Saulep D; Mackay F; Pers JO
Autoimmun Rev; 2010 Jul; 9(9):604-8. PubMed ID: 20457281
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of circulating anti-N-methyl-
Tay SH; Fairhurst AM; Mak A
Autoimmun Rev; 2017 Feb; 16(2):114-122. PubMed ID: 27988431
[TBL] [Abstract][Full Text] [Related]
33. Sjögren's syndrome: a systemic autoimmune disease.
Negrini S; Emmi G; Greco M; Borro M; Sardanelli F; Murdaca G; Indiveri F; Puppo F
Clin Exp Med; 2022 Feb; 22(1):9-25. PubMed ID: 34100160
[TBL] [Abstract][Full Text] [Related]
34. Sjögren's syndrome: still not fully understood disease.
Maślińska M; Przygodzka M; Kwiatkowska B; Sikorska-Siudek K
Rheumatol Int; 2015 Feb; 35(2):233-41. PubMed ID: 24985362
[TBL] [Abstract][Full Text] [Related]
35. Mesenchymal stem cell transplantation ameliorates Sjögren's syndrome via suppressing IL-12 production by dendritic cells.
Shi B; Qi J; Yao G; Feng R; Zhang Z; Wang D; Chen C; Tang X; Lu L; Chen W; Sun L
Stem Cell Res Ther; 2018 Nov; 9(1):308. PubMed ID: 30409219
[TBL] [Abstract][Full Text] [Related]
36. Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.
Segal BM; Nazmul-Hossain AN; Patel K; Hughes P; Moser KL; Rhodus NL
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Jun; 111(6):673-80. PubMed ID: 21497524
[TBL] [Abstract][Full Text] [Related]
37. [Sjögren's syndrome (SS), a review of the subject and saliva as a diagnostic method].
Riega-Torres JC; Villarreal-Gonzalez AJ; Ceceñas-Falcon LÁ; Salas-Alanis JC
Gac Med Mex; 2016; 152(3):371-80. PubMed ID: 27335194
[TBL] [Abstract][Full Text] [Related]
38. JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjögren's Syndrome.
Lee J; Lee J; Kwok SK; Baek S; Jang SG; Hong SM; Min JW; Choi SS; Lee J; Cho ML; Park SH
Arthritis Rheumatol; 2018 Dec; 70(12):2057-2066. PubMed ID: 29927095
[TBL] [Abstract][Full Text] [Related]
39. Cytokines in Sjogren's syndrome: potential therapeutic targets.
Roescher N; Tak PP; Illei GG
Ann Rheum Dis; 2010 Jun; 69(6):945-8. PubMed ID: 20410069
[TBL] [Abstract][Full Text] [Related]
40. Emerging biological therapies in primary Sjogren's syndrome.
Ramos-Casals M; Brito-Zerón P
Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
